Literature DB >> 25583977

Mutations within the mepA operator affect binding of the MepR regulatory protein and its induction by MepA substrates in Staphylococcus aureus.

Bryan D Schindler1, Susan M Seo1, Ivan Birukou2, Richard G Brennan2, Glenn W Kaatz3.   

Abstract

The expression of mepA, encoding the Staphylococcus aureus MepA multidrug efflux protein, is repressed by the MarR homologue MepR. Repression occurs through binding of two MepR dimers to an operator with two homologous and closely approximated pseudopalindromic binding sites (site 1 [S1] and site 2 [S2]). MepR binding is impeded in the presence of pentamidine, a MepA substrate. The effects of various mepA operator mutations on MepR binding were determined using electrophoretic mobility shift assays and isothermal titration calorimetry, and an in vivo confirmation of the effects observed was established for a fully palindromic operator mutant. Altering the S1-S2 spacing by 1 to 4 bp severely impaired S2 binding, likely due to a physical collision between adjacent MepR dimers. Extension of the spacing to 9 bp eliminated the S1 binding-mediated DNA allostery required for efficient S2 binding, consistent with positive cooperative binding of MepR dimers. Binding of a single dimer to S1 was maintained when S2 was disrupted, whereas disruption of S1 eliminated any significant binding to S2, also consistent with positive cooperativity. Palindromization of binding sites, especially S2, enhanced MepR affinity for the mepA operator and reduced MepA substrate-mediated MepR induction. As a result, the on-off equilibrium between MepR and its binding sites was shifted toward the on state, resulting in less free MepR being available for interaction with inducing ligand. The selective pressure(s) under which mepA expression is advantageous likely contributed to the accumulation of mutations in the mepA operator, resulting in the current sequence from which MepR is readily induced by MepA substrates.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583977      PMCID: PMC4336350          DOI: 10.1128/JB.02558-14

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  23 in total

1.  Structural basis for cooperative DNA binding by two dimers of the multidrug-binding protein QacR.

Authors:  Maria A Schumacher; Marshall C Miller; Steve Grkovic; Melissa H Brown; Ronald A Skurray; Richard G Brennan
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

2.  Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter.

Authors:  Glenn W Kaatz; Rama V Thyagarajan; Susan M Seo
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region.

Authors:  K Evans; L Adewoye; K Poole
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

4.  The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage.

Authors:  B N Kreiswirth; S Löfdahl; M J Betley; M O'Reilly; P M Schlievert; M S Bergdoll; R P Novick
Journal:  Nature       Date:  1983 Oct 20-26       Impact factor: 49.962

5.  Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus.

Authors:  Christos Kosmidis; Bryan D Schindler; Pauline L Jacinto; Diixa Patel; Karanpreet Bains; Susan M Seo; Glenn W Kaatz
Journal:  Int J Antimicrob Agents       Date:  2012-07-04       Impact factor: 5.283

6.  Evaluation of a tetracycline-inducible promoter in Staphylococcus aureus in vitro and in vivo and its application in demonstrating the role of sigB in microcolony formation.

Authors:  B T Bateman; N P Donegan; T M Jarry; M Palma; A L Cheung
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

7.  Plasmids designed to alter the antibiotic resistance expressed by insertion mutations in Bacillus subtilis, through in vivo recombination.

Authors:  M Steinmetz; R Richter
Journal:  Gene       Date:  1994-05-03       Impact factor: 3.688

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Binding of purified multiple antibiotic-resistance repressor protein (MarR) to mar operator sequences.

Authors:  R G Martin; J L Rosner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  Structural mechanism of transcription regulation of the Staphylococcus aureus multidrug efflux operon mepRA by the MarR family repressor MepR.

Authors:  Ivan Birukou; Susan M Seo; Bryan D Schindler; Glenn W Kaatz; Richard G Brennan
Journal:  Nucleic Acids Res       Date:  2013-11-28       Impact factor: 16.971

View more
  4 in total

Review 1.  MarR family proteins are important regulators of clinically relevant antibiotic resistance.

Authors:  Grace A Beggs; Richard G Brennan; Mehreen Arshad
Journal:  Protein Sci       Date:  2019-11-14       Impact factor: 6.725

Review 2.  Multidrug efflux pumps in Staphylococcus aureus and their clinical implications.

Authors:  Soojin Jang
Journal:  J Microbiol       Date:  2016-01-05       Impact factor: 3.422

3.  The MarR-Type Regulator Rdh2R Regulates rdh Gene Transcription in Dehalococcoides mccartyi Strain CBDB1.

Authors:  Lydia Krasper; Hauke Lilie; Anja Kublik; Lorenz Adrian; Ralph Golbik; Ute Lechner
Journal:  J Bacteriol       Date:  2016-11-04       Impact factor: 3.490

4.  Resistance in In Vitro Selected Tigecycline-Resistant Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Is Driven by Mutations in mepR and mepA Genes.

Authors:  Andrei Nicoli Gebieluca Dabul; Juliana Sposto Avaca-Crusca; Daria Van Tyne; Michael S Gilmore; Ilana Lopes Baratella Cunha Camargo
Journal:  Microb Drug Resist       Date:  2017-10-17       Impact factor: 3.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.